Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers H > Headlines for Halozyme Therapeutics Inc. > News item |
Halozyme initiated by Rodman & Renshaw at market outperform
Halozyme Therapeutics Inc. coverage was initiated by Rodman & Renshaw analyst Matthew Murray with a market outperform rating and a price target on the stock of $2.88 per share. Halozyme shares Tuesday were up $0.07, or 3.76%, at $1.93 on volume of 10,400 shares versus the three-month running average of 37,927.7 shares.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.